ARASEC Trial Validates Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

The ARASEC trial, offers compelling evidence for darolutamide combined with androgen deprivation therapy as a treatment option for men with metastatic hormone-sensitive prostate cancer. This Phase 2 study tackled a challenging ethical dilemma in modern clinical trial design: how to evaluate a new treatment when randomizing patients to receive only standard ADT would be considered substandard care in the United States.

The investigators adopted an innovative approach by enrolling 223 patients who all received darolutamide at 600 mg twice daily plus ADT, then comparing their outcomes to a carefully matched external control group drawn from the historical CHAARTED trial. Using propensity score matching based on six key prognostic factors including age, performance status, disease extent, prior local therapy, Gleason score, and PSA level, researchers created balanced groups of 160 patients each. This methodology allowed for a scientifically rigorous comparison while ensuring all enrolled patients received active treatment intensification.

The efficacy results presented at AUA 2026 demonstrated substantial clinical benefit across multiple endpoints. Patients receiving darolutamide plus ADT experienced a 71% reduction in their risk of disease progression or death compared to the matched control group receiving ADT alone, with a hazard ratio of 0.29. Overall survival showed a 50% reduction in death risk, while progression to castration-resistant disease was reduced by 74%. Radiological progression or death occurred 70% less frequently in the darolutamide-treated patients.

These findings are particularly meaningful in the current treatment landscape where multiple androgen receptor pathway inhibitors have demonstrated efficacy in metastatic hormone-sensitive prostate cancer, yet treatment intensification remains underutilized in clinical practice. The ARASEC trial provides prospective evidence specific to a contemporary US patient population, offering clinicians and patients another validated option when considering doublet therapy without chemotherapy.

The safety profile observed in ARASEC aligned with previous darolutamide studies, showing no unexpected adverse events. Among the matched population, 58% of treatment-related side effects were mild to moderate in severity, and only 8% of patients discontinued darolutamide due to adverse events. This favorable tolerability reflects darolutamide’s pharmacological properties, including limited penetration of the blood-brain barrier and low potential for drug interactions.

ARASEC complements the existing evidence base for darolutamide in different clinical scenarios. While the Phase III ARASENS trial established darolutamide plus ADT and docetaxel as a standard triplet regimen for metastatic hormone-sensitive prostate cancer, ARASEC addresses the important clinical question of whether the doublet combination offers sufficient benefit for patients in whom chemotherapy is inappropriate or undesired. The trial also works in tandem with ARANOTE, a Phase III study conducted outside the United States examining the same doublet combination.

The use of an external control arm derived from historical trial data represents an increasingly relevant approach to clinical trial design in oncology, particularly when ethical considerations preclude randomization to inferior therapies. The rigorous propensity score matching methodology employed in ARASEC successfully balanced known prognostic factors between groups, with standardized mean differences below 0.1 for all variables except PSA level. This statistical approach strengthens confidence that the observed treatment effects reflect genuine therapeutic benefit rather than baseline imbalances between populations.

Source.